Flyrcado FDA Approval History
FDA Approved: Yes (First approved September 27, 2024)
Brand name: Flyrcado
Generic name: flurpiridaz F 18
Dosage form: Injection
Company: GE HealthCare
Treatment for: Positron Emission Tomography Imaging
Flyrcado (flurpiridaz F 18) is a positron emission tomography (PET) myocardial perfusion imaging (MPI) agent used for the detection of coronary artery disease.
- Flyrcado is indicated for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Development timeline for Flyrcado
| Date | Article |
|---|---|
| Sep 27, 2024 | Approval FDA Approves Flyrcado (flurpiridaz F 18) Radioactive Diagnostic for Enhanced Diagnosis of Coronary Artery Disease |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.